Myhre L, Gautvik K M
Acta Endocrinol (Copenh). 1979 Jul;91(3):449-61. doi: 10.1530/acta.0.0910449.
Two antisera with known region specificities have been used to characterize calcitonin immunoreactivity (iCT) in serum of patients with medullary thyroid carcinoma (MCT). Antiserum I which was raised against the synthetic hormone (1-32 amino acid residues), contained heterogeneous populations of immunoglobulins directed predominantly against carboxy-terminal sequences of the hormone, but the antiserum reacted also with the amino-terminal fragment (1-10 amino acid residues). Antiserum II, which was raised against the carboxy-terminal hormone fragment (11-32 amino acid residues) reached equally well with the intact hormone and the C-terminal fragment, but showed negligible binding of the amino terminal fragment. Antiserum I measured therefore both amino-terminal and carboxy-terminal sequences of calcitonin while antiserum II measured only carboxy-terminal amino acid sequences. In 40 patients with MCT, antiserum I measured usually the highest concentration of serum iCT suggesting the presence of non-uniform hormone immunoreactivity. The different molecular forms of circulating iCT in 7 MCT patients were explored by using antiserum I after gel filtration on Sephadex G-100. The patients who were selected on basis of iCT measurement in serum using antiserum I and II, could be divided into 3 groups which showed characteristic iCT profiles. Group 1, in which antiserum II measured a higher concentration of serum iCT, contained predominantly (60-70%) small fragments of calcitonin immunoreactivity. On the other hand, in the sera of group 3 in which antisera I measured an equal or the highest concentrations, the dominant form of the hormone consisted of molecular sequences equal to or larger than the intact hormone (90%). In group 2, the two antisera measured an equal amount of serum iCT and molecular forms consisting mostly of larger hormone fragments dominated (50%). All the patients were normocalcaemic in spite of frequently grossly elevated serum iCT, and 33 out of 36 patients had normal serum immunoreactive parathyroid hormone.
使用两种具有已知区域特异性的抗血清来表征甲状腺髓样癌(MCT)患者血清中的降钙素免疫反应性(iCT)。抗血清I是针对合成激素(1 - 32个氨基酸残基)产生的,包含主要针对激素羧基末端序列的异质免疫球蛋白群体,但该抗血清也与氨基末端片段(1 - 10个氨基酸残基)发生反应。抗血清II是针对羧基末端激素片段(11 - 32个氨基酸残基)产生的,与完整激素和C末端片段的反应同样良好,但对氨基末端片段的结合可忽略不计。因此,抗血清I可检测降钙素的氨基末端和羧基末端序列,而抗血清II仅检测羧基末端氨基酸序列。在40例MCT患者中,抗血清I通常检测到血清iCT的最高浓度,提示存在不均一性的激素免疫反应性。通过在Sephadex G - 100上进行凝胶过滤后使用抗血清I,对7例MCT患者循环iCT的不同分子形式进行了研究。根据使用抗血清I和II对血清iCT的测量结果选择的患者可分为3组,每组呈现出特征性的iCT谱。第1组中抗血清II检测到血清iCT的浓度较高,主要包含(60 - 70%)降钙素免疫反应性的小片段。另一方面,在抗血清I检测到相等或最高浓度的第3组患者血清中,激素的主要形式由等于或大于完整激素的分子序列组成(90%)。在第2组中,两种抗血清检测到等量的血清iCT,且主要由较大激素片段组成的分子形式占主导(50%)。尽管血清iCT常常显著升高,但所有患者血钙正常,36例患者中有33例血清甲状旁腺激素免疫反应性正常。